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Abstract Risk factors for the newly identified ‘‘intrinsic’’
breast cancer subtypes (luminal A, luminal B, basal-like and
human epidermal growth factor receptor 2-positive/estro-
gen receptor-negative) were determined in the Carolina
Breast Cancer Study, a population-based, case–control
study of African-American and white women. Immuno-
histochemical markers were used to subtype 1,424 cases of
invasive and in situ breast cancer, and case subtypes were
compared to 2,022 controls. Luminal A, the most common
subtype, exhibited risk factors typically reported for breast
cancer in previous studies, including inverse associations
for increased parity and younger age at first full-term
pregnancy. Basal-like cases exhibited several associations
that were opposite to those observed for luminal A,
including increased risk for parity and younger age at first
term full-term pregnancy. Longer duration breastfeeding,
increasing number of children breastfed, and increasing
number of months breastfeeding per child were each asso-
ciated with reduced risk of basal-like breast cancer, but not
luminal A. Women with multiple live births who did not
breastfeed and women who used medications to suppress
lactation were at increased risk of basal-like, but not
luminal A, breast cancer. Elevated waist-hip ratio was
associated with increased risk of luminal A in postmeno-
pausal women, and increased risk of basal-like breast can-
cer in pre- and postmenopausal women. The prevalence of
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basal-like breast cancer was highest among premenopausal
African-American women, who also showed the highest
prevalence of basal-like risk factors. Among younger
African-American women, we estimate that up to 68% of
basal-like breast cancer could be prevented by promoting
breastfeeding and reducing abdominal adiposity.
Keywords Breast cancer subtypes  molecular
epidemiology
Introduction
Almost two decades ago, Wetzels et al. [1] used immuno-
histochemical markers to identify a subset of breast tumors
that exhibited a ‘‘basal cell phenotype,’’ in that the tumors
expressed cytokeratins normally found only in the cell layer
lying closest to the basement membrane of the mammary
gland epithelium. Perou and colleagues [2–4] further
characterized ‘‘basal-like’’ breast cancer as one of five
principal subtypes identified in a supervised gene expres-
sion analysis of breast tumors. The ‘‘intrinsic’’ subtypes
consisted of estrogen receptor (ER)-positive (luminal) tu-
mors, two separate groups of ER–negative tumors [basal-
like and human epidermal growth factor receptor 2 (HER2)-
positive] and a group with a pattern resembling normal
breast [2, 3]. Luminal tumors stained for cytokeratins nor-
mally expressed in the upper, more differentiated breast
epithelial layer (i.e., keratins 8/18), while basal-like tumors
expressed cytokeratin 5/6. Luminal tumors were further
subdivided into luminal A (ER-positive, HER2-negative)
and luminal B (ER-positive, HER2-positive). The ‘‘intrin-
sic’’ subtypes have been reproduced across a variety of
microarray platforms [5, 6] and validated in numerous pa-
tient datasets from around the world [7, 8]. The ‘‘intrinsic’’
classification system showed significant agreement in pre-
dicting clinical outcomes when compared with three other
gene-expression based classification schemes, suggesting
that these profiling methods identify distinct, stable biologic
properties of breast tumors [9].
To investigate the prevalence of ‘‘intrinsic’’ subtypes in
large, population-based datasets where fresh tumor tissue
was not available, immunohistochemistry (IHC) surrogate
markers were developed that could be applied to formalin-
fixed, paraffin-embedded tumor blocks [10]. We applied
these IHC markers to tumor blocks collected as part of the
Carolina Breast Cancer Study (CBCS), a population-based,
case–control conducted among African-American and white
women in North Carolina. The ‘‘intrinsic’’ subtypes were
observed in invasive [11] as well as in situ [12] breast cancer.
The presence of the basal-like subtype in in situ breast
cancer suggests that this phenotype is established early in
breast carcinogenesis, and could therefore reflect a distinct
pathway for disease etiology. In the CBCS, the prevalence of
basal-like breast cancer was highest among premenopausal
African-American women, while luminal A was most
common among postmenopausal white women [11].
In the present analysis, we used exposure information
collected from the CBCS to identify risk factors for the five
breast cancer subtypes, with an emphasis on comparing
two of the most distinct subtypes, namely luminal A and
basal-like. We estimated the prevalence of risk factors for
basal-like breast cancer among controls in the CBCS
dataset, and estimated population attributable fractions that
may be useful for prioritizing interventions to reduce the
incidence of basal-like breast cancer, particularly among
younger African-American women.
Methods
Study design and sampling
The CBCS is a population-based, case–control study con-
ducted in 24 counties of North Carolina that combines
molecular biology and population-based epidemiology to
understand the causes of breast cancer [13]. Cases were
identified from the North Carolina Central Cancer Registry,
and controls were identified using Drivers’ License and
Medicare beneficiary lists [14]. Participants provided in-
formed consent using documents approved by the Institu-
tional Review Board at the University of North Carolina
School of Medicine. Women with invasive breast cancer
and population controls were enrolled during Phase 1
(1993–1996) and Phase 2 (1996–2001). Randomized
recruitment was used to oversample younger and African-
American cases so that sample sizes would be sufficient for
separate analyses [15]. Women with carcinoma in situ
(CIS) and population controls were enrolled only during
the latter time period (1996–2001). All cases of CIS
[including ductal carcinoma in situ (DCIS), DCIS with
microinvasion to a depth of 2 mm, and lobular carcinoma
in situ (LCIS)] were eligible. Controls were frequency
matched to cases by age and race using randomized
recruitment [15]. Participants ranged in age from 20 to
74 years. Contact, cooperation, and overall response rates
have previously been published for each phase of the study
[16]. The portion of the CBCS designed to evaluate inva-
sive breast cancer included 1,803 cases (787 African-
American, 1,016 white) and 1,564 controls (718 African-
American, 846 white), with overall response rates of 76%
for cases and 55% for controls. The portion of the CBCS
that evaluated carcinoma in situ (CIS) comprised 508 cases
(107 African-American, 401 white) and 458 controls (70
African-American, 388 white), with overall responses rates
of 83% for cases and 65% for controls.
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In-person interviews and body size measurements
In-person interviews were conducted for cases and controls
by trained nurses. Participants were asked detailed infor-
mation about family history of cancer and reproductive
history, including age at onset of regular menstruation, age
at first full-term pregnancy (AFFTP) and number of chil-
dren, breastfeeding and onset of menopause. Women were
asked to compare their weight to their peers during fifth
grade, and to provide information on recreational physical
activity, household or farm chores, and walking or biking
to school at age 12, and frequency of recreational physical
activity as an adult. Additional information was obtained
on environmental exposures (smoking, alcohol use), hor-
mone use (oral contraceptives; hormone replacement
therapy, HRT), and socioeconomic status (income, educa-
tion, occupational history) [17–20]. Participants were also
asked about prior medical conditions, including diabetes
mellitus.
Measurements were taken of waist circumference, hip
circumference and body weight at the time of interview.
Tumor blocks and immunohistochemistry assays
Women with invasive and in situ breast cancer were asked
for permission to obtain relevant medical records and
pathology reports (to confirm eligibility) and access to tu-
mor blocks (for centralized review, sectioning and immu-
nohistochemistry assays) [21]. The distributions of breast
cancer ‘‘intrinsic’’ subtypes was previously published for
496 cases from Phase 1 of the invasive portion [11] and
245 cases from the CIS portion [12]. For the present
analysis, we added data from an additional 653 cases of
invasive breast cancer from Phase 2 and 30 cases from the
CIS study. The additional CIS cases included three women
with DCIS, 17 with DCIS with microinvasion and 10 with
LCIS that were not included in the previous analysis [12].
In total, this article therefore presents data from 1,424 cases
(1,149 invasive and 275 in situ) with sufficient tissue for
IHC analysis, comprising 62% (1,424/2,311) of enrolled
CBCS cases. A comparison of cases with IHC marker data
to those without yielded no statistically significant differ-
ences for age, menopausal status, family history of breast
cancer, or other covariates, with the following exceptions:
African Americans and patients with later stage at diag-
nosis were more highly represented in the IHC marker
dataset compared to cases without marker data. African-
American women in the CBCS tended to be diagnosed with
later stage tumors than white women, and tumors with
adequate tissue for IHC assays tended to be slightly larger
than tumors with insufficient tissue [11].
Tumor blocks were sectioned and stained for a panel of
IHC markers at the Immunohistochemistry Core Labora-
tory, University of North Carolina (UNC). For invasive
cases, ER and progesterone receptor (PR) status were ab-
stracted from medical records for 80% of cases and
determined using IHC assays performed at UNC for the
remaining cases [22]. For in situ cases, ER status was
determined using IHC. For all cases, IHC assays for HER2,
HER1 (EGFR), and CK5/6 assays were conducted using
assay procedures and cutpoints for positivity as previously
described [11, 12]. Subtype definitions for invasive cases
were based upon five IHC markers: luminal A (ER+ and/or
PR+, HER2–), luminal B (ER+ and/or PR+, HER2+), ba-
sal-like (ER–, PR–, HER2–, HER1+ and/or CK5/6+),
HER2+/ER– (ER–, PR–, HER2+) and unclassified (nega-
tive for all five markers). For in situ disease, four IHC
markers were used: luminal A (ER+, HER2–), luminal B
(ER+, HER2+), basal-like (ER–, HER2–, HER1+ and/or
CK5/6+), HER2+/ER– (ER–, HER2+) and unclassified
(negative for all four markers). PR status was not deter-
mined for in situ cases in order to preserve tissue sections.
For in situ breast cancer, PR+ tumors are almost always
ER+. In one recent study of DCIS, ER and PR status were
strongly correlated (P < 0.001), and fewer than 1% of tu-
mors were ER– and PR+ [23].
Statistical analysis
Race was categorized based upon self-report as African-
American or white. The latter category included fewer than
2% of participants who listed their race as Native Ameri-
can, Asian, mixed or other race, while the remainder
classified themselves as white. Menopausal status was
determined using information from the interview. Women
younger than 50 years were classified as postmenopausal if
they had undergone natural menopause, bilateral oopho-
rectomy, or irradiation to the ovaries, otherwise they were
classified as premenopausal. For women aged 50 or older,
menopausal status was assigned based upon cessation of
menstruation.
Body mass index (BMI) was calculated as body weight
(kg)/height (m)2 and used as a measure of general adi-
posity. Categories for BMI were based upon National
Heart, Lung, and Blood Institute (NHLBI) cutpoints (<25
normal or underweight, 25–29 overweight, ‡30 obese)
[24]. Waist-hip ratio (WHR) was calculated as the ratio of
waist to hip circumference (cm) and used as a measure of
abdominal adiposity. Cutpoints for WHR were tertiles
based upon the distribution in controls. Other covariates
were defined as previously reported [14, 17–20]. Briefly,
women who had smoked at least 100 cigarettes in their
lifetime, consumed any alcoholic beverages, or used oral
contraceptives or HRT at any time were classified as ‘‘ever
users.’’ Breastfeeding was categorized according to the
total lifetime number of months of breastfeeding, the
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number of children breastfed, months of breastfeeding per
child, and use of medications to suppress lactation. The
average number of children breastfed and months breast-
feeding per child were calculated for each woman based
upon information obtained for each live birth. Women were
also asked about lactation failure or other problems with
breastfeeding.
The prevalence of breast cancer subtypes (among cases)
and participant characteristics and risk factors (cases and
controls) were adjusted for the sampling probabilities used
to select eligible participants, as implemented in SUDAAN
version 9.0.1 (Research Triangle Institute, Research Tri-
angle Park, NC). Distributions across categories were
compared using adjusted Chi square tests.
Unconditional logistic regression was used to calculate
odds ratios (ORs) as a measure of association, as imple-
mented in SAS version 8.2 (SAS Institute, Cary NC). Odds
ratios were calculated among cases only using luminal A,
the most common subtype, as the comparison group. Case-
only analyses using disease subtypes are a useful explor-
atory tool to uncover etiologic heterogeneity [25]. In the
present application, the case-only OR estimates the relative
strength of association between a risk factor and a given
disease subtype (basal-like, luminal B, HER2+/ER–, or
unclassified) versus the same exposure and luminal A (ratio
of ORs). Case-only ORs were adjusted for age and/or race,
and supplemental analyses were conducted adjusting for
American Joint Committee on Cancer (AJCC) stage at
diagnosis (stage 0 or in situ, 1, 2, 3 + 4).
Odds ratios comparing cases and controls were calcu-
lated to further investigate the etiology of the five subtypes
(estimate risk ratios), with each subtype separately com-
pared to all controls (N = 2,022). Potential confounders
were selected based upon prior knowledge, directed acyclic
graphs (DAGs) [26, 27] and by selecting variables that
resulted in a 10% or greater change in the beta estimate for
the exposures of interest. Prior knowledge dictated that
ORs for waist circumference and WHR be adjusted for
BMI [28, 29]. Odds ratios for BMI and WHR were also
calculated after stratifying on menopausal status, and
postmenopausal women were further stratified based upon
use of HRT [28]. DAGs dictated that we not adjust parity
and lactation ORs for WHR or BMI, since the latter vari-
ables could lie on a causal pathway between the exposures
of interest and breast cancer. The list of exposures of
interest and potential confounders included family history,
reproductive history, measures of body size, weight gain,
physical activity, environmental exposures, hormone use,
and socioeconomic status (education and family income).
When the analysis was restricted to parous women, ORs
for breastfeeding variables were attenuated slightly and
estimates were less precise, therefore results are presented
using the more stable referent category of nulliparous
women. Odds ratios for lifetime duration of breastfeeding
used a cutpoint of 4 months since no additional protective
effects were observed for longer duration. Odds ratios for
breastfeeding variables did not differ among women who
reported having trouble breastfeeding or being unable to
lactate. Odds ratios for reproductive and breastfeeding
variables were similar (although less precise) after strati-
fying on race and menopausal status, and ORs did not
differ substantially when CIS cases and controls were re-
moved from the analysis.
To evaluate multiplicative interaction, likelihood ratio
tests (LRTs) were used to calculate P-values comparing
models with main effects to models with main effects plus
relevant interaction term/s. Likelihood ratio tests were not
significant for the interaction of the exposures of interest
and race or menopausal status. In particular, for basal-like
breast cancer, LRTs yielded non-significant results for the
interaction of parity and race (P = 0.22), parity and
menopausal status (P = 0.46), parity/breastfeeding com-
posite variable and race (P = 0.32), and parity/breast-
feeding and menopausal status (P = 0.41). Therefore,
results are presented combining African and white women,
and pre- and postmenopausal women. For BMI and WHR,
ORs were similar after stratifying on race and LRTs were
not significant.
Tests for trend were conducted by calculating P-values
for the beta coefficient in logistic regression models with
exposure coded as an ordinal variable. All statistical tests
were two-sided with an alpha level of 0.05.
Population attributable fractions (PAFs) for basal-like
breast cancer were estimated using the method of Bruzzi
et al. [30]. PAFs combine information on the relative risk
(estimated in the present study by the OR) and prevalence
for a given exposure or group of exposures in the dataset of
interest. The 95% CIs for PAFs were calculated using the
bootstrap method described by Rockhill et al. [31]. Briefly,
1,000 random samples, with replacement, stratified on
case–control status were repeatedly drawn from the origi-
nal dataset. PAFs were calculated for each random sample,
resulting in 1,000 PAFs, and the 2.5th and 97.5th percen-
tiles of the frequency distribution served as the approxi-
mate 95% CI for the original PAF estimate.
Results
Distribution of breast cancer subtypes
The distribution of ‘‘intrinsic’’ breast cancer subtypes in
the combined CBCS datasets (invasive and in situ) is
presented in Table 1. Among the 1,424 cases with IHC
marker data, 796 (56%) were classified as luminal A, 225
(16%) were basal-like, 116 (8%) were HER2+/ER–, 137
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(10%) were luminal B, and the remaining 150 cases (10%)
were unclassified. For in situ tumors, all cases of LCIS
were classified as luminal A, while DCIS with microin-
vasion was divided among all five subtypes, similar to the
distributions reported previously for pure DCIS [12]. The
distribution of ‘‘intrinsic’’ subtypes differed significantly
by race and menopausal status (P < 0.0001) (Table 1).
Postmenopausal white women showed the highest preva-
lence of luminal A, while premenopausal African-Ameri-
can women exhibited the highest prevalence of basal-like
breast cancer.
Case-only odds ratios
Case-only ORs comparing each subtype to luminal A are
presented in Table 2, and were minimally adjusted for age
and/or race. Compared to luminal A, basal-like cases
tended to be younger, African-American, and have
younger age at menarche, higher parity, younger age at
first full-term pregnancy, shorter duration breastfeeding
and higher BMI and WHR (especially among premeno-
pausal women). HER2+/ER–, luminal B, and unclassified
cases also tended to be younger than luminal A cases.
HER2+/ER– cases were slightly more likely to be Afri-
can-American but less likely to be premenopausal.
Luminal B cases had older age at first full-term preg-
nancy, and were more likely to consume alcohol and use
HRT, and less likely to be obese or have central distri-
bution of fat. Unclassified cases were more likely to be
African-American, and had younger age at menarche and
increased parity compared with luminal A. There were no
significant interactions between race and menopausal
status for each of the four subtypes compared to luminal
A. Odds ratios did not differ after adjustment for stage at
diagnosis (data not shown).
Case–control odds ratios
Odds ratios for luminal A cases versus controls, and basal-
like cases versus controls, are presented in Table 3. Youn-
ger age at menarche was positively associated with basal-
like, but not luminal A, breast cancer. Parity, regardless of
the number of live births, and younger AFFTP (before
26 years) showed inverse associations with luminal A
breast cancer. In contrast, significant, positive increases in
risk of basal-like breast cancer were observed with
increasing number of live births and younger age at first
full-term pregnancy. Inverse associations were observed for
breastfeeding and basal-like breast cancer, with significant
trends for lifetime duration of lactation, number of children
breastfed, and average number of months breastfeeding per
child. Use of lactation suppressants was positively associ-
ated with basal-like but not luminal A breast cancer.
The composite variable ‘‘parity and lactation’’ exhibited
a strong positive association for basal-like breast cancer
among women who had 1–2 children and never breastfed,
and a slightly stronger association for women with 3 or
more children who never breastfed (Table 3). The com-
posite variable ‘‘parity and AFFTP’’ showed stronger po-
sitive associations with basal-like breast cancer for parous
women with AFFTP <26 than women with AFFTP of 26 or
greater. In contrast, inverse associations with luminal A
were observed for both composite variables. A composite
variable that included parity, AFFTP and breastfeeding
demonstrated that higher parity and lack of breastfeeding
were the main contributors to increased risk of basal-like
breast cancer, with little additional contribution from
younger AFFTP (data not shown). Among parous women,
ORs for breastfeeding and AFFTP did not change after
mutual adjustment, and there was no evidence for inter-
action between the two variables.
Table 1 Distribution of breast
cancer subtypes according to
race and menopausal status
a Numbers in table are
observed numbers (not adjusted
for sampling probabilities)
b Percentages in table are
adjusted for sampling
probabilities
c Chi square test adjusted for
sampling probabilities
Breast cancer
subtype
African-American
premenopausal
Na (%)b
African-American
postmenopausal
N (%)
White
premenopausal
N (%)
White
postmenopausal
N (%)
Luminal A
N = 796
108 (41.4) 179 (56.3) 216 (57.4) 293 (66.5)
Basal-like
N = 225
70 (27.2) 52 (16.0) 54 (14.5) 49 (9.3)
HER2+/ER–
N = 116
22 (8.4) 26 (7.7) 24 (5.6) 44 (6.0)
Luminal B
N = 137
19 (7.3) 26 (8.7) 46 (12.4) 46 (10.7)
Unclassified
N = 150
41 (15.7) 38 (11.3) 38 (10.1) 33 (7.5)
Total: 1,424
Pc <0.0001
260 (100) 321 (100) 378 (100) 465 (100)
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Additional analyses were conducted for timing of
pregnancy and breast cancer subtypes. The average interval
between pregnancies did not differ across the five breast
cancer subtypes (P = 0.11). The proportion of women with
three or more pregnancies and at least one interval between
pregnancies of a year or less was 21% for luminal A and
20% for basal-like cases. The proportion of women who
were pregnant or diagnosed with breast cancer within
1 year of being pregnant did not differ across the five
subtypes (P = 0.14). However, time between last preg-
nancy and breast cancer diagnosis was longer for luminal A
compared to the other case subtypes (P = 0.002), which
may be attributable to the fact that luminal A cases were
older relative to the other groups.
For BMI, ORs were slightly inverse or close to the null
for both luminal A and basal-like breast cancer (Table 3).
Among postmenopausal women, increasing tertiles of
WHR were positively associated with luminal A, however,
WHR showed stronger positive associations with basal-
like breast cancer for pre- and postmenopausal women.
Among postmenopausal women, results for BMI and WHR
were similar after stratification on use of HRT (data not
shown).
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Table 3 Case–control odds ratios comparing luminal A cases versus
controls and basal-like cases versus controls
Risk factor Controls Luminal A Basal-like
N N OR (95% CI) N OR (95% CI)
Age at menarchea
‡13 1,072 406 Referent 100 Referent
<13 942 389 1.1 (0.9–1.3) 125 1.4 (1.1–1.9)
Parityb
Nulliparous 230 132 Referent 26 Referent
1 child 343 122 0.7 (0.5–1.0) 38 1.7 (0.9–3.0)
2 670 259 0.7 (0.6–1.0) 79 1.8 (1.1–3.1)
‡3 779 283 0.7 (0.5–0.9) 82 1.9 (1.1–3.3)
Trend test P = 0.07 P = 0.04
Age at first full-term pregnancyb
Nulliparous 230 132 Referent 26 Referent
<26 1,354 477 0.7 (0.5–0.9) 159 1.9 (1.2–3.2)
‡26 435 184 0.9 (0.6–1.2) 39 1.5 (0.8–2.8)
Breastfeedingc
Never 1,223 500 Referent 158 Referent
Ever 799 296 0.9 (0.7–1.0) 67 0.7 (0.5–1.0)
Lifetime duration lactationc
Never 1,223 500 Referent 158 Referent
>0 to 3 months 280 92 0.7 (0.6–0.9) 27 0.9 (0.6–1.4)
‡4 516 204 0.9 (0.7–1.1) 40 0.7 (0.4–0.9)
Trend test P = 0.26 P = 0.03
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Among cases and controls in the CBCS, elevated BMI,
WHR, and waist circumference were positively associated
with history of diabetes mellitus (data not shown). How-
ever, the prevalence of diabetes mellitus did not differ
across the five breast cancer subtypes (P = 0.59). Women
who reported a gain in adiposity since childhood had
increased risk of basal-like breast cancer, while women
who decreased in adiposity were at reduced risk. Specif-
ically, women with an elevated WHR measured at inter-
view (‡0.77) who reported being thinner than their peers
in fifth grade had elevated risk of basal-like breast cancer
(adjusted OR = 2.2, 95% CI 1.5–3.4), relative to women
with lower WHR who were thinner than their peers in
fifth grade. In contrast, women who reported being hea-
vier than their peers in fifth grade and whose current
WHR was low exhibited an inverse association with ba-
sal-like breast cancer (OR = 0.5, 95% CI 0.2–1.4). The
comparable ORs were close to the null for luminal A
breast cancer. The proportion of women reporting gains in
adiposity since fifth grade was higher among African-
American controls (63%) compared to white controls
(42%) (P = 0.0002).
Table 3 continued
Risk factor Controls Luminal A Basal-like
N N OR (95% CI) N OR (95% CI)
Number of children breastfedc
Never 1,223 500 Referent 158 Referent
1 384 121 0.7 (0.6–0.9) 35 0.8 (0.6–1.2)
‡2 415 175 1.0 (0.8–1.2) 32 0.6 (0.4–0.9)
Trend test P = 0.33 P = 0.03
Ave. number months breastfeeding per childc
Never 1,223 500 Referent 158 Referent
0–3.9 480 172 0.8 (0.7–1.0) 42 0.8 (0.6–1.2)
‡4 316 124 0.9 (0.7–1.2) 25 0.6 (0.4–0.9)
Trend test P = 0.20 P = 0.03
Lactation suppressant usec
Never 1,033 447 Referent 102 Referent
Ever 989 349 0.9 (0.8–1.1) 123 1.5 (1.1–2.0)
Parity and lactationc
Nulliparous 230 132 Referent 26 Referent
1–2, never 625 232 0.7 (0.6–0.9) 81 1.8 (1.1–3.0)
1–2, ever 388 149 0.7 (0.5–0.9) 36 1.1 (0.6–2.0)
‡3, never 368 136 0.7 (0.5–0.9) 51 1.9 (1.1–3.3)
‡3, ever 411 147 0.7 (0.5–0.9) 31 1.3 (0.7–2.3)
Parity and AFFTPc
Nulliparous 230 132 Referent 26 Referent
1–2, <26 653 221 0.6 (0.5–0.8) 82 1.7 (1.0–2.8)
1–2, 26+ 360 160 0.8 (0.6–1.1) 34 1.2 (0.7–2.2)
‡3, <26 701 256 0.7 (0.5–0.9) 77 1.6 (1.0–2.8)
‡3, 26+ 75 24 0.6 (0.3–1.0) 5 1.2 (0.4–3.5)
BMI (kg/m2)d
Overall
<25 615 288 Referent 64 Referent
25–29 609 208 0.7 (0.6–0.9) 66 1.0 (0.7–1.5)
‡30 751 277 0.8 (0.6–1.0) 88 0.8 (0.6–1.2)
Trend test P = 0.04 P = 0.30
Premenopausal
<25 292 138 Referent 34 Referent
25–29 233 75 0.7 (0.5–1.0) 35 1.1 (0.7–1.9)
‡30 318 105 0.7 (0.5–1.0) 50 1.0 (0.6–1.8)
Trend test P = 0.08 P = 0.96
Postmenopausal
<25 323 150 Referent 30 Referent
25–29 376 133 0.8 (0.6–1.0) 31 0.8 (0.5–1.4)
‡30 433 172 0.8 (0.6–1.1) 38 0.6 (0.3–1.1)
Trend test P = 0.22 P = 0.10
WHRe
Overall
<0.77 615 210 Referent 40 Referent
0.77–0.83 646 268 1.3 (1.1–1.7) 89 2.3 (1.5–3.5)
‡0.84 732 306 1.5 (1.1–1.9) 91 2.3 (1.4–3.6)
Trend test P = 0.005 P = 0.002
Table 3 continued
Risk factor Controls Luminal A Basal-like
N N OR (95% CI) N OR (95% CI)
Premenopausal
<0.77 324 122 Referent 25 Referent
0.77–0.83 277 113 1.3 (0.9–1.8) 56 2.6 (1.5–4.5)
‡0.84 253 86 1.2 (0.8–1.8) 41 1.8 (1.0–3.4)
Trend test P = 0.41 P = 0.07
Postmenopausal
<0.77 291 88 Referent 15 Referent
0.77–0.83 369 155 1.5 (1.1–2.1) 33 1.8 (0.9–3.6)
‡0.84 479 220 1.8 (1.3–2.6) 50 2.7 (1.3–5.4)
Trend test P = 0.002 P = 0.006
a Adjusted for offsets, age (continuous), race (African-American,
white), menopausal status (pre-, postmenopausal), family history (yes,
no), alcohol use (ever, never), smoking duration (never, £10, 11–20,
>20 years), oral contraceptive use (ever, never), parity (nulliparous,
1–2,3+), breastfeeding (ever, never)
b Adjusted for offsets, age, race, menopausal status, family history,
alcohol use, smoking duration, oral contraceptive use, age at men-
arche (<13, 13+), breastfeeding
c Adjusted for offsets, age, race, menopausal status, family history,
alcohol use, smoking duration, oral contraceptive use, age at men-
arche
d Adjusted for offsets, age, race, menopausal status (overall analy-
sis), family history, alcohol use, smoking duration, oral contraceptive
use, age at menarche, parity breastfeeding
e Adjusted for offsets, age, race, menopausal status (overall analy-
sis), family history, alcohol use, smoking duration, oral contraceptive
use, age at menarche, parity breastfeeding and BMI (continuous)
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Case–control ORs for the luminal B, HER2+/ER– and
unclassified subtypes were largely similar to luminal A,
with the following exceptions. Luminal B cases showed a
stronger positive association with alcohol use than the
other subtypes (adjusted case–control OR = 1.7, 95% CI
1.1–2.7), and no association with elevated WHR. Whereas
luminal A, basal-like and HER2+ subtypes showed weak
inverse associations with postmenopausal HRT, the case–
control OR for luminal B was slightly above the null
(OR = 1.1, 95% CI 0.7–1.9).
Prevalence of risk factors for basal-like breast cancer
The distribution of risk factors for basal-like breast cancer
differed among the four race-menopausal status groups
(Table 4). Prevalence estimates are based upon controls,
and represent weighted estimates for women residing in the
24-county region of North Carolina sampled by the CBCS.
Premenopausal African-American women showed the
highest prevalence of menarche before age 13 years and
never breastfeeding, and the lowest prevalence of lifetime
breastfeeding of 4 months or longer, ‡2 children breastfed
and ‡4 months breastfeeding per child.
Even stronger differences between African-American
and white women emerged when we subdivided younger
women into two age groups, less than age 40 and aged
40 to 50 (Table 5). Younger African-American women
had a higher prevalence of each of the principal risk
factors for basal-like breast cancer: higher parity, lower
breastfeeding, higher parity combined with lower
breastfeeding, greater use of lactation suppressants, and
elevated WHR. Among parous women, African Ameri-
cans in each age group reported younger AFFTP, fewer
children breastfed, and fewer months breastfeeding per
child.
Population attributable fractions
Population attributable fractions for basal-like breast can-
cer were estimated for the two most easily modified risk
factors: breastfeeding (never versus ever) and elevated
WHR (‡0.77 vs. <0.77). For the entire study population,
the PAF was 53% (95% CI 33.3–68.9). Among the four
age-race groups, PAFs for basal-like breast cancer were
68% (95% CI 30.0–90.1) for premenopausal African-
American women, 57% (–20.5 to 93.1) for postmenopausal
African-American women, 37% (–15.1 to 68.4) for pre-
menopausal white women, and 38% (–12.5 to 74.5) for
postmenopausal African-American women. The PAF for a
set of risk factors can be interpreted as the proportion of
breast cancer that would be eliminated if the entire study
population was moved from the exposed to the unexposed
level for each of the relevant exposures.
Discussion
In a population-based epidemiologic study of African-
American and white women, we observed differing mag-
nitudes of association for several breast cancer risk factors
when we subdivided cases according to the ‘‘intrinsic’’
subtypes (luminal A, luminal B, basal-like, HER2+/ER–
and unclassified). Exploratory case-case comparisons were
most striking for luminal A versus basal-like breast cancer,
and analyses comparing cases and controls yielded several
potential risk factors for basal-like cancer that differed in
magnitude and direction in comparison with luminal A.
Parity combined with lack of breastfeeding, early-onset
menarche, younger AFFTP, use of lactation suppressants,
elevated WHR and gain in adiposity since childhood were
positively associated with basal-like breast cancer. Nota-
Table 4 Distributions of
selected basal-like risk factors
among controls according to
race and menopausal status
a Percentages in table are
adjusted for sampling
probabilities
b Chi square test adjusted for
sampling probabilities
Characteristica African-American
premenopausal
(%)
African-American
postmenopausal
(%)
White
premenopausal
(%)
White
postmenopausal
(%)
Age at menarche <13
Pb =0.03
54 36 45 46
Never breastfed
P = 0.0001
76 66 61 61
Lifetime duration breastfeeding
‡4 months
P < 0.0001
13 27 29 21
Parous women
‡2 children breastfed
P < 0.0001
13 24 33 19
‡4 months breastfeeding
per child
P < 0.0001
10 18 34 12
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bly, each of these risk factors was more prevalent among
younger African-American women, as represented by
controls in the CBCS. The results suggest that a large part
of the racial difference in the distribution of the ‘‘intrinsic’’
breast cancer subtypes may be attributable to differing
distributions of specific risk factors related to reproductive
history, breastfeeding, adiposity and weight gain.
In a recent article, Anderson et al. [32] examined inci-
dence rates for breast tumors with poor prognostic features
(ER and PR negative, tumor size greater than 2.0 cm,
lymph node positive, high grade) compared to tumors with
a more favorable prognosis (hormone receptor positive,
size 2.0 cm or less, lymph node negative, low grade).
Incidence rates were higher for poor prognosis tumors until
ages 30–44, followed by a plateau at age 50 and a sub-
sequent reduction, whereas incidence rates for more
favorable prognosis tumors were higher in women aged
50 years and continued to rise as women grew older. The
authors hypothesized that high- and low-risk breast tumors
represent distinct subtypes of breast cancer with separate
risk factor profiles and/or cell types of origin. In a similar
vein, Bernards and Weinberg [33] cited biologic data to
support a theory that breast cancer prognosis is ‘‘preor-
dained by the spectrum of mutations that progenitor cells
acquire relatively early in tumorigenesis; that is, some
cancers start out on the wrong foot’’ [33: page 823].
Therefore, incidence rates and genetic data together sup-
port the idea that poor prognosis breast tumors in younger
women have a different underlying etiology than more
favorable breast cancers in older women. This hypothesis is
especially relevant for younger African-American women,
for whom breast cancer incidence remains high compared
to white women [34] and mortality from hormone receptor
negative, high grade breast cancer is a major public health
problem [35–37].
Increased parity and younger AFFTP have been asso-
ciated with increased risk of breast cancer among younger
African-American women in several studies [38–40]
including the CBCS [41], but not in others [42] (for review,
see Swanson et al. [35]). We observed a statistically sig-
nificant increase in risk of basal-like breast cancer with
increasing number of children, a relationship that was not
observed for luminal A breast cancer. The relationship
between parity and basal-like breast cancer was not con-
fined to younger women, and basal-like cases were no more
likely to be diagnosed following a pregnancy than luminal
A cases. Thus, the positive association between parity and
basal-like breast cancer was not restricted to the well-
documented short-term increase in risk of breast cancer
following live birth [41, 43]. Nor did the increase in risk
appear to be attributable to younger age at menarche or
younger AFFTP which have also been associated with in-
creased risk of breast cancer in younger African-American
women [35]. Rather, the increased risk for basal-like breast
cancer with increasing parity appeared to be largely con-
fined to women who did not breastfeed (Table 3). Fur-
thermore, the effects of increased parity and lower
breastfeeding, and the contrast between basal-like and
luminal A breast cancer, were observed across all four age-
race groups. In the case-only analysis comparing basal-like
versus luminal A breast cancer, the OR for parity ‡3 and no
breastfeeding (adjusted for age and race) was 1.9 (95% CI
1.1–3.4) for all women. In the four patient groups, ORs
(adjusted for age) were 2.2 (95% CI 0.7–6.6) for pre-
Table 5 Distributions of
selected basal-like risk factors
in African-American and white
controls under age 40 and aged
40–49
a Percentages in table are
adjusted for sampling
probabilities
b Chi square test comparing
African-American and white
controls in each age group,
adjusted for sampling
probabilities
Characteristica African-American
age <40 (%)
White age
<40 (%)
African-American
age 40–49 (%)
White age
40–49 (%)
Parity ‡3 24
Pb = 0.45
13 41
P = 0.0001
19
Never breastfed 82
P = 0.01
61 75
P = 0.0003
61
Parity ‡3 and never breastfed 18
P = 0.002
5 30
P < 0.0001
7
Lactation suppressants, ever use 34
P = 0.06
19 61
P = 0.0003
42
Parous women: AFFTP <26 78
P = 0.04
59 86
P < 0.0001
61
Parous women 9 37 14 27
‡2 children breastfed P < 0.0001 P < 0.0001
4 months breastfeeding per child 9 39 10 26
P < 0.0001 P < 0.0001
WHR ‡0.77 61
P = 0.31
46 80
P < 0.0001
55
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menopausal African-American women, 1.9 (95% CI 0.6–
5.9) for postmenopausal African-American women, 1.8
(95% CI 0.5–7.0) for premenopausal white women, and 1.7
(95% CI 0.5–5.6) in postmenopausal white women.
The Collaborative Group on Hormonal Risk Factors in
Breast Cancer [44] determined that breastfeeding exerts a
protective effect on overall breast cancer risk beyond that
of parity alone. Potential mechanisms include induction of
terminal differentiation and/or removal of initiated breast
epithelial cells, removal of estrogens via breast fluid,
excretion of carcinogenic agents, delay in ovulation, and
changes in breast pH [45]. Use of lactation suppressants
has also been associated with increased breast cancer risk,
although results were not consistent across studies [45].
Several lines of evidence suggest a link between basal-like
breast cancer and lack of breastfeeding. Symmans et al.
[46] found that over-expression of the basal-like marker,
GABApi, was associated with younger age at diagnosis and
shorter duration of breastfeeding among Hispanic breast
cancer patients. BRCA1, but not BRCA2, mutation carriers
show a high prevalence of basal-like breast cancer (for
review, see Tischowitz and Foulkes [47]). In one study,
BRCA1 carriers who breastfed for 1 year or longer were
less likely to develop breast cancer than mutation carriers
who did not breastfeed; no effect of breastfeeding was seen
for BRCA2 carriers [48]. As suggested by Tischowitz and
Foulkes [47], full-term pregnancy followed by failure to
breastfeed or reduced duration of breastfeeding could result
in retention of initiated progenitor cells that ultimately die
or differentiate during lactation, and these retained cells
could presumably develop into basal-like breast tumors.
Pregnancy confers specific gene expression signatures on
breast tissue and may effect the distribution and differen-
tiation of potential breast cancer stem cells [49], but the
effects of lactation on gene expression and the differenti-
ation status of mammary epithelial cells are not well
understood.
The other strong risk factor for basal-like breast cancer
identified in the CBCS was WHR. Elevated WHR was
associated with a strong increase in risk of basal-like breast
cancer among pre- and postmenopausal women, and a
more modest increase for luminal A among postmeno-
pausal women. When the two components of WHR were
examined separately, elevated waist circumference showed
a strong positive association with basal-like breast cancer
among pre- and postmenopausal women, while ORs for hip
circumference were slightly inverse (data not shown).
Waist circumference and WHR serve as surrogates for
abdominal adiposity: waist circumference is correlated
with the amount of visceral and subcutaneous fat, while
WHR is used as an index of the relative accumulation of
abdominal versus gluteal fat [28]. Previous epidemiologic
studies have shown a consistent association between ele-
vated central adiposity and increased breast cancer risk in
postmenopausal women [50], while results for premeno-
pausal women have been less consistent [28, 29].
Abdominal adiposity is correlated with hyperinsulinemia
and insulin resistance among African-American and white
women [51, 52], and insulin resistance has been hypothe-
sized to increase breast cancer risk in premenopausal wo-
men through increased mitotic activity and enhanced cell
proliferation in breast epithelial tissue [28]. There are
currently no biologic data linking insulin resistance with
basal-like breast cancer, and our data do not support an
association between prior history of diabetes mellitus and
increased risk of basal-like disease. However, overexpres-
sion of the leptin receptor is found in breast tumors with
high grade [53], a feature associated with basal-like breast
cancer.
Our results combining recalled weight in fifth grade with
measured WHR at the time of interview suggest that
weight gain and/or gain in abdominal adiposity over a
woman’s lifetime may contribute to increased risk of basal-
like breast cancer. Previous studies reported a stronger
association between weight gain and risk of postmeno-
pausal compared with premenopausal breast cancer [54,
55]. Slattery et al. [56] found that weight gain since age 15
and elevated WHR were both associated with increased
risk of ER–negative breast cancer. The latter results were
presented combining pre- and postmenopausal women, and
HER2 status was not included in tumor subtyping.
In addition to Slattery et al. [56], the work of other
researchers suggests that risk factors for breast cancer
differ depending upon hormone receptor status of the tu-
mor [22, 57–62]. Although differences were slight, the
results suggest that traditional risk factors based upon
reproductive history are associated with increased risk of
hormone-receptor positive disease [63, 64], which is con-
sistent with our findings for the luminal A breast cancer
subtype. Other studies stratified cases based upon HER2
positivity; but strong differences were not noted (for re-
view, see Huang et al. [65]).
Previous studies reported a higher frequency of hor-
mone-receptor negative breast cancer and later stage at
diagnosis among African-American and other minority
women compared with white women in the United States
[37, 60, 61]. Recently, researchers at the California Cancer
Registry found that breast cancer patients with the ‘‘triple
negative’’ (ER–, PR–, HER2–) phenotype were more likely
to be under age 40, African-American, or Hispanic [66].
‘‘Triple negative’’ breast cancer was more frequent among
women of lower socioeconomic status. The authors used
the ‘‘triple negative’’ phenotype as a partial surrogate for
basal-like breast cancer, since IHC data were limited to ER,
PR and HER2 status. Individual-level data were not
available on breast cancer risk factors, and socioeconomic
134 Breast Cancer Res Treat (2008) 109:123–139
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status was assigned at the census block level using address
at the time of diagnosis. In the CBCS, lower socioeco-
nomic status (based upon income and education) was not
associated with increased frequency of basal-like breast
cancer. However, lower socioeconomic status was strongly
associated with several risk factors for basal-like cancer,
including lower breastfeeding (P < 0.0001) and elevated
WHR (P < 0.0001). Future studies are needed to determine
whether the increased prevalence of triple negative breast
cancer found among Hispanic women in California may be
attributable to reproductive history, breastfeeding, central
adiposity and other basal-like risk factors.
Only one previous population-based study examined
risk factors for breast cancer based upon the joint distri-
bution of ER, PR, HER2, HER1, and CK5/6, the five IHC
markers used to identify the ‘‘intrinsic’’ subtypes in the
CBCS. Using data collected from a case–control study in
Poland, Yang et al. [67] calculated ORs for each of the five
breast cancer subtypes versus controls. Results were simi-
lar to the CBCS, in that luminal A and basal tumors
showed distinct risk factor profiles, with luminal A show-
ing associations typically described for breast cancer as a
whole. The authors reported positive associations for
younger age at menarche and parity with basal-like cancer,
but breastfeeding was not addressed. An inverse associa-
tion between elevated BMI and luminal A breast cancer
was observed among premenopausal women, but no asso-
ciation was seen for basal-like breast cancer, similar to our
results. The authors did not examine WHR. Age at men-
arche and parity were associated with luminal A but not
HER2+/ER– breast cancer. In the CBCS, case–control ORs
for HER2+/ER– were almost identical to luminal A, with
the exception of a slight inverse association for elevated
WHR among postmenopausal women. Yang et al. [67]
reported a stronger association with family history for ba-
sal-like breast cancer compared to the other subtypes. In
our study, associations with family history were nearly
identical across the five subtypes, with age and race-ad-
justed case–control ORs equal to 1.5 (95% CI 1.2–1.9) for
luminal A and 1.7 (95% CI 1.1–2.5) for basal-like breast
cancer. The only other epidemiologic study to examine risk
factors for the ‘‘intrinsic’’ breast cancer subtypes was a
population-based case series from Sweden [8] in which the
authors subdivided cases based upon gene expression
profiling. Current users of HRT were over-represented in
the ‘‘normal-like’’ or ‘‘unclassified’’ breast tumor subtype.
In the CBCS, the case–control OR for postmenopausal
HRT and the unclassified subtype was 1.0 (95% CI 0.6–
1.7).
A primary focus of the present analysis was to identify
modifiable risk factors that could be targeted to reduce the
risk of basal-like breast cancer, particularly among younger
African-American women who have the highest incidence
of this breast cancer subtype. Mortality rates are higher
among younger African-American breast cancer patients,
and the disparity in breast cancer outcomes has worsened
over time [34]. Since basal-like breast cancer confers a
poor prognosis [6, 11], understanding the etiology of this
breast cancer subtype is an important public health prob-
lem. We estimated that approximately two-thirds (68%) of
basal-like breast cancer in younger African-American
women (and over half of the disease in the general popu-
lation) could be prevented by interventions that increase
breastfeeding and decrease abdominal adiposity.
There are a number of limitations to PAF estimates,
since they are based upon very strong assumptions. First,
PAFs estimate the proportion of disease that would be
eliminated if the entire population was moved from the
exposed to the unexposed level for each of the relevant risk
factors, assuming that the exposures in question are causal.
One or more of the associations observed in this article
could have resulted from recall bias, confounding, or other
sources of systematic error. However, it is unlikely that
exposure misclassification would be differential by breast
cancer subtype, and extensive analyses were conducted to
address the possibility of confounding. Analyses of par-
ticipants with and without IHC marker data, and previous
analyses comparing participants and non-participants in the
CBCS [68], suggest that selection bias is also unlikely.
Data from subsequent population-based studies that utilize
‘‘intrinsic’’ subtypes will provide important information as
to whether the associations observed in this article are
causal. Second, the afore-mentioned PAF estimates assume
that all women in the population are able to breastfeed
children and reduce their WHR below 0.77. Clearly, not all
women will have children, and there may be significant
barriers to both breastfeeding and reducing abdominal
adiposity. Third, the calculations assume independence of
breastfeeding and WHR from other risk factors, such that
the remaining risk factors for basal-like breast cancer are
not changed by modifying the two exposures in question.
Finally, PAFs should not be interpreted as the proportion of
disease that can be ‘‘explained’’ by any specified group of
risk factors. Since PAFs do not necessarily add up to 100%,
it is possible that many additional exposures could con-
tribute to the risk of basal-like disease. Despite these lim-
itations, PAF calculations perform an important function
for public health in that they provide a framework for
greater understanding of disease etiology in populations,
and stimulate the public health community to evaluate the
feasibility of primary prevention strategies [69].
There are several additional limitations to the present
analysis. BRCA1 carrier status was determined for only a
small sample of women in the CBCS [70]. It is possible
that some basal-like cases were BRCA1 mutation carriers,
but this number is likely to be very small given the low
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frequency of BRCA1 carriers in the CBCS [70] and other
population-based studies [71]. Another caveat is that IHC
surrogates were used to subtype CBCS cases since fresh
tumor samples were unavailable to perform gene expres-
sion profiling. The IHC surrogates have been validated in
another study population, showing excellent agreement
with gene expression profiling [10], and they have been
utilized in other studies to detect the presence of the five
‘‘intrinsic’’ breast cancer subtypes [67, 72–74]. Although
tumor blocks tended to be available from cases with larger
tumors, the case-only subtype comparisons did not differ
when we adjusted for stage at diagnosis. Sample size was
small for many of the subsets of interest, and our results
need to be replicated in other population-based studies. Our
study was limited largely to African-American and white
women, and studies of the epidemiology of basal-like
breast cancer among Hispanic women and other minority
groups is an important area for future investigation.
Interventions to reduce the risk of basal-like breast
cancer have strong prior justification. In a summary of
existing data on breast cancer among younger African-
American women, Bernstein et al. [43] targeted increasing
breastfeeding, losing weight, and increasing physical
activity as the most effective ways of reducing disease risk.
Our study adds further support for these recommendations.
The benefits of breastfeeding for mother and child are well-
documented [75]. The Centers for Disease Control and
Prevention Goals for Healthy People 2010 lists a target of
75% of mothers breastfeeding in the immediate postpartum
period, with at least 50% continuing to breastfeed for
6 months [76]. As observed in the CBCS, the prevalence of
breastfeeding is reported to be lower among younger
African-American women compared to white women [42,
43, 76]. Lack of information about benefits, restrictions
surrounding employment, and social pressures limit
breastfeeding [75], and maternal obesity decreases initia-
tion as well as continuation of lactation [77]. Teenage
mothers may experience particular barriers to breastfeed-
ing. In the CBCS, the proportion of controls who reported
having a child before the age of 20 was higher among
African-American (45%) compared with white women
(23%, P < 0.0001). Thus, the reasons for lower prevalence
of breastfeeding among younger African American women
are complex, and interventions to encourage breastfeeding
must operate at the level of the community, the workplace,
and society at large [78].
Public health interventions aimed at avoiding over-
nutrition, promoting a healthy diet, and encouraging
physical activity [79] could impact the incidence of basal-
like breast cancer, especially programs that target exces-
sive weight gain. Reduction in abdominal adiposity would
provide additional benefits, including reduced risk of dia-
betes mellitus and heart disease [28, 50]. The prevalence of
obesity is increasing among pregnant women [80], leading
to increased risk of hypertension and perinatal mortality
[81]. A variety of barriers at the school and neighborhood
level [82] may need to be overcome to promote physical
activity among young girls.
Interventions to reduce risk of basal-like breast cancer
would take years to have an impact, especially if early
stages of carcinogenesis were targeted. Measures to im-
prove survival for patients with basal-like breast cancer
will have a more immediate impact. Increased adiposity at
the time of diagnosis can confer a worse prognosis for
younger breast cancer patients [83], and this poor prognosis
may be especially relevant for women with basal-like
disease. Timely and effective treatment is vitally important
for patients with basal-like breast cancer, and a variety of
new drugs are being evaluated in clinical trials [84].
However, African-American women historically suffer
from reduced access to quality health care, delays in
diagnosis and treatment, and low enrollment in clinical
trials, and these disparities need to be addressed more
effectively in the future [85–88]. Health care providers
need to be aware of the possibility of a breast cancer
subtype with distinct etiology and worse prognosis.
Unfortunately, clinicians may overlook breast cancer
among younger women when patients do not present with a
‘‘classic’’ set of risk factors [35]. Determination of the
sensitivity and specificity of screening mammography for
basal-like breast cancer would have important implications
for detection and diagnosis of breast cancer, particularly in
younger women. Finally, risk assessment models for breast
cancer may need to be modified to identify women at high-
risk for the basal-like subtype.
Conclusions
The ‘‘intrinsic’’ breast cancer subtypes, luminal A and
basal-like, exhibit distinct risk factors. Basal-like breast
cancer is associated with early-onset menarche, younger
age at first full-term pregnancy, high parity combined with
lack of breast feeding, and abdominal adiposity. In contrast
to recent commentaries suggesting that basal-like breast
cancer represents the ‘‘exclusive’’ property of a specific
age and racial group by virtue of genetics [89–91], our data
show that the basal-like subtype is present in younger white
breast cancer patients as well as older African-American
and white patients at appreciable frequencies. Furthermore,
distributional differences of basal-like breast cancer by age
and race appear to be largely attributable to varying dis-
tributions of the currently identified risk factors for basal-
like breast cancer. Programs aimed at promoting breast-
feeding and reducing abdominal adiposity would reduce
the number of cases of basal-like breast cancer among all
136 Breast Cancer Res Treat (2008) 109:123–139
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women. Such interventions would be particularly relevant
for younger African-American women, among whom the
prevalence of risk factors for basal-like breast cancer is
high.
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